T. Baumert, Rapid induction of virus-neutralizing antibodies and viral 9

J. Mckeating, C. Schuster, and T. Baumert, Inhibition of hepatitis C virus infection 14

T. Pietschmann, A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis et al., Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras, Proceedings of the National Academy of Sciences, vol.103, issue.19, pp.7408-7421, 2006.
DOI : 10.1073/pnas.0504877103

A. Kaul, I. Woerz, P. Meuleman, G. Leroux-roels, and R. Bartenschlager, Cell culture 21 adaptation of hepatitis C virus and in vivo viability of an adapted variant, J Virol, vol.2281, pp.13168-79, 2007.

S. Foung, Affinity maturation to improve human monoclonal antibody 25 MS# GASTRO-D-11-01111.R1 neutralization potency and breadth against hepatitis C virus, J Biol Chem, vol.1286, pp.44218-44251, 2011.

G. Deleage, euHCVdb: the European hepatitis C virus database
URL : https://hal.archives-ouvertes.fr/hal-00314934

A. Patel, Monoclonal antibody AP33 defines a broadly neutralizing epitope on 9

E. Schnober, M. Zeisel, P. Carolla, H. Barth, H. Blum et al., the hepatitis C virus E2 envelope glycoprotein, J Virol, vol.79, pp.11095-104, 2005.

A. Schuster, C. Stoll-keller, F. Doffoel, M. Dreux, M. Baumert et al., Neutralizing 13 host responses in hepatitis C virus infection target viral entry at postbinding 14 steps and membrane fusion, Gastroenterology, vol.135, issue.15, pp.1719-1728, 2008.

S. Abrignani and S. Foung, Human monoclonal antibodies that inhibit binding of 17 hepatitis C virus E2 protein to CD81 and recognize conserved conformational 18 epitopes, J Virol, vol.74, issue.19, pp.10407-10423, 2000.

A. Alter, H. Rice, C. Foung, and S. , Mutations in hepatitis C virus E2 located 21 outside the CD81 binding sites lead to escape from broadly neutralizing 22 antibodies but compromise virus infectivity, J Virol Dimitrova M, vol.83, issue.12, pp.6149-60, 2009.